As someone who’s seen Alzheimer’s up close, this research offers a glimmer of hope. Focused ultrasound could open new doors, literally, by safely clearing harmful plaques without drugs. It’s a step toward treatments that ease symptoms and protect memories. I’m hopeful for what this means for families like mine.

Donanemab, a monoclonal antibody targeting amyloid plaques, significantly slowed Alzheimer’s progression in a major trial. By preserving cognition and daily function, it offers new hope for early Alzheimer’s patients, despite some risks like amyloid-related imaging abnormalities.